OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?
Alice Boilève, Marc Hilmi, Matthieu Delaye, et al.
Cancers (2021) Vol. 13, Iss. 11, pp. 2708-2708
Open Access | Times Cited: 24
Alice Boilève, Marc Hilmi, Matthieu Delaye, et al.
Cancers (2021) Vol. 13, Iss. 11, pp. 2708-2708
Open Access | Times Cited: 24
Showing 24 citing articles:
Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
Alessandro Rizzo, Antonio Cusmai, Gennaro Gadaleta‐Caldarola, et al.
Expert Review of Gastroenterology & Hepatology (2022) Vol. 16, Iss. 4, pp. 333-339
Closed Access | Times Cited: 79
Alessandro Rizzo, Antonio Cusmai, Gennaro Gadaleta‐Caldarola, et al.
Expert Review of Gastroenterology & Hepatology (2022) Vol. 16, Iss. 4, pp. 333-339
Closed Access | Times Cited: 79
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
Alessandro Rizzo, Angela Dalia Ricci, Alessandro Di Federico, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 97
Alessandro Rizzo, Angela Dalia Ricci, Alessandro Di Federico, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 97
PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?
Alessandro Rizzo, Angela Dalia Ricci
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 4, pp. 415-423
Closed Access | Times Cited: 91
Alessandro Rizzo, Angela Dalia Ricci
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 4, pp. 415-423
Closed Access | Times Cited: 91
Clinically approved combination immunotherapy: Current status, limitations, and future perspective
Ligong Lu, Meixiao Zhan, Xian-Yang Li, et al.
Current Research in Immunology (2022) Vol. 3, pp. 118-127
Open Access | Times Cited: 51
Ligong Lu, Meixiao Zhan, Xian-Yang Li, et al.
Current Research in Immunology (2022) Vol. 3, pp. 118-127
Open Access | Times Cited: 51
Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers
Ruyin Chen, Dandan Zheng, Qiong Li, et al.
Cancer Letters (2022) Vol. 546, pp. 215853-215853
Closed Access | Times Cited: 21
Ruyin Chen, Dandan Zheng, Qiong Li, et al.
Cancer Letters (2022) Vol. 546, pp. 215853-215853
Closed Access | Times Cited: 21
Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic Insights
James Yu, Robin Park, Richard D. Kim
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 1105-1127
Open Access | Times Cited: 9
James Yu, Robin Park, Richard D. Kim
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 1105-1127
Open Access | Times Cited: 9
Integrated single-cell and bulk RNA-Seq analysis enhances prognostic accuracy of PD-1/PD-L1 immunotherapy response in lung adenocarcinoma through necroptotic anoikis gene signatures
Ping Sui, Xueping Liu, Cheng Zhong, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Ping Sui, Xueping Liu, Cheng Zhong, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer
Hong-Sik Kim, Hana Kim, Ryul Kim, et al.
Technology in Cancer Research & Treatment (2021) Vol. 20
Open Access | Times Cited: 17
Hong-Sik Kim, Hana Kim, Ryul Kim, et al.
Technology in Cancer Research & Treatment (2021) Vol. 20
Open Access | Times Cited: 17
An m6A-Related lncRNA Signature Predicts the Prognosis of Hepatocellular Carcinoma
Zhenyu Zhang, Fangkai Wang, Jianlin Zhang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 12
Zhenyu Zhang, Fangkai Wang, Jianlin Zhang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 12
Real-life data on biliary tract cancers in France: The nested Amber study from the French ACABi GERCOR PRONOBIL retro-prospective, observational cohort
Matthieu Delaye, Alice Boilève, Julie Henriques, et al.
Digestive and Liver Disease (2024)
Open Access | Times Cited: 2
Matthieu Delaye, Alice Boilève, Julie Henriques, et al.
Digestive and Liver Disease (2024)
Open Access | Times Cited: 2
Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for Hepatocellular Carcinoma
Marie Dupuy, Sarah Iltache, Benjamin Rivière, et al.
Cancers (2022) Vol. 14, Iss. 2, pp. 402-402
Open Access | Times Cited: 8
Marie Dupuy, Sarah Iltache, Benjamin Rivière, et al.
Cancers (2022) Vol. 14, Iss. 2, pp. 402-402
Open Access | Times Cited: 8
Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study
Yunchao Wang, Xiaobo Yang, Yanyu Wang, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 7, pp. 2197-2204
Open Access | Times Cited: 4
Yunchao Wang, Xiaobo Yang, Yanyu Wang, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 7, pp. 2197-2204
Open Access | Times Cited: 4
Targeted Therapy with Polymeric Nanoparticles in PBRM1-Mutant Biliary Tract Cancers: Harnessing DNA Damage Repair Mechanisms
Hrushikesh Wagh, Sankha Bhattacharya
Critical Reviews in Oncology/Hematology (2024) Vol. 204, pp. 104505-104505
Closed Access | Times Cited: 1
Hrushikesh Wagh, Sankha Bhattacharya
Critical Reviews in Oncology/Hematology (2024) Vol. 204, pp. 104505-104505
Closed Access | Times Cited: 1
Bile detection of squamous cell carcinoma antigen (SCCA) in extrahepatic cholangiocarcinoma
Enrico Gringeri, Alessandra Biasiolo, M. Di Giunta, et al.
Digestive and Liver Disease (2022) Vol. 55, Iss. 4, pp. 534-540
Closed Access | Times Cited: 5
Enrico Gringeri, Alessandra Biasiolo, M. Di Giunta, et al.
Digestive and Liver Disease (2022) Vol. 55, Iss. 4, pp. 534-540
Closed Access | Times Cited: 5
LncRNAs as Theragnostic Biomarkers for Predicting Radioresistance in Cancer: A Systematic Review and Meta-Analysis
Ping Lin, Wenmin Xing, Qian Ren, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 4
Ping Lin, Wenmin Xing, Qian Ren, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 4
État des lieux des pratiques de prise en charge des cancers des voies biliaires en France : résultats de l'enquête nationale ACABi
Matthieu Delaye, Éric Assenat, Emmanuel Boleslawski, et al.
Bulletin du Cancer (2022) Vol. 109, Iss. 11, pp. 11S3-11S10
Open Access | Times Cited: 4
Matthieu Delaye, Éric Assenat, Emmanuel Boleslawski, et al.
Bulletin du Cancer (2022) Vol. 109, Iss. 11, pp. 11S3-11S10
Open Access | Times Cited: 4
Current state of radiomics in hepatobiliary and pancreatic malignancies
Mahip Grewal, Taha M. Ahmed, Ammar A. Javed
Artificial Intelligence Surgery (2023) Vol. 3, Iss. 4, pp. 217-32
Open Access | Times Cited: 1
Mahip Grewal, Taha M. Ahmed, Ammar A. Javed
Artificial Intelligence Surgery (2023) Vol. 3, Iss. 4, pp. 217-32
Open Access | Times Cited: 1
Therapeutic significance of tumor microenvironment in cholangiocarcinoma: focus on tumor-infiltrating T lymphocytes
Chaoqun Li, Lei Bie, Muhua Chen, et al.
Exploration of Targeted Anti-tumor Therapy (2023) Vol. 4, Iss. 6, pp. 1310-1327
Open Access | Times Cited: 1
Chaoqun Li, Lei Bie, Muhua Chen, et al.
Exploration of Targeted Anti-tumor Therapy (2023) Vol. 4, Iss. 6, pp. 1310-1327
Open Access | Times Cited: 1
Immunotherapeutic strategies in hepatopancreatobiliary cancers
Massimiliano Salati, Alessandro Rizzo, Angela Dalia Ricci, et al.
Elsevier eBooks (2024), pp. 103-124
Closed Access
Massimiliano Salati, Alessandro Rizzo, Angela Dalia Ricci, et al.
Elsevier eBooks (2024), pp. 103-124
Closed Access
Portrait moléculaire dans les cancers des voies biliaires : enquête nationale de pratique auprès des plateformes françaises
Matthieu Delaye, Cindy Neuzillet, Jean‐Christophe Sabourin
Bulletin du Cancer (2024) Vol. 111, Iss. 11, pp. 1030-1037
Open Access
Matthieu Delaye, Cindy Neuzillet, Jean‐Christophe Sabourin
Bulletin du Cancer (2024) Vol. 111, Iss. 11, pp. 1030-1037
Open Access
Signal enhancement ratio of CE-MRI: a potential biomarker of survival after hepatic arterial infusion chemotherapy in biliary tract cancers
Kanglian Zheng, Shijie Fu, Boyu Leng, et al.
Insights into Imaging (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 1
Kanglian Zheng, Shijie Fu, Boyu Leng, et al.
Insights into Imaging (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 1
Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon?
Alessandro Rizzo, Angela Dalia Ricci
Expert Review of Precision Medicine and Drug Development (2022) Vol. 7, Iss. 1, pp. 50-57
Closed Access | Times Cited: 1
Alessandro Rizzo, Angela Dalia Ricci
Expert Review of Precision Medicine and Drug Development (2022) Vol. 7, Iss. 1, pp. 50-57
Closed Access | Times Cited: 1
Apport de l'immunothérapie dans le traitement des cancers des voies biliaires avancés
Matthieu Delaye, Astrid Lièvre, Cindy Neuzillet
Bulletin du Cancer (2022) Vol. 109, Iss. 11, pp. 11S11-11S20
Open Access | Times Cited: 1
Matthieu Delaye, Astrid Lièvre, Cindy Neuzillet
Bulletin du Cancer (2022) Vol. 109, Iss. 11, pp. 11S11-11S20
Open Access | Times Cited: 1
Histopathological Evaluation and Molecular Diagnostic Tests for Peritoneal Metastases with Unknown Primary Site—a Review
Aditi Bhatt, Suniti Mishra, Olivier Gléhen
Indian Journal of Surgical Oncology (2022) Vol. 14, Iss. S1, pp. 15-29
Open Access
Aditi Bhatt, Suniti Mishra, Olivier Gléhen
Indian Journal of Surgical Oncology (2022) Vol. 14, Iss. S1, pp. 15-29
Open Access
